Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
ROCKVILLE, Md., May 02, 2017 -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a conference call on Tuesday, May 9, 2017 at 4:30 p.m. ET to discuss its financial results for the quarter ended March 31, 2017 and recent operational highlights.
To access the live call by phone, dial (855) 422-8964 (domestic) or (210) 229-8819 (international), and enter the passcode 13743533. To access a live or recorded webcast of the call, please visit the “Investors” section of the REGENXBIO website at www.regenxbio.com. The recorded webcast will be available for approximately 30 days following the call.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of product candidates in multiple therapeutic areas.
CONTACT: Investors Heather Savelle, 646-395-3734 [email protected] Media Adam Pawluk, 202-591-4063 [email protected]
